Endo International PLC (NASDAQ:ENDP) Issues FY17 Earnings Guidance
Endo International PLC (NASDAQ:ENDP) issued an update on its FY17 earnings guidance on Tuesday morning. The company provided EPS guidance of $3.35-3.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.53. The company issued revenue guidance of $3.38-3.53 billion, compared to the consensus revenue estimate of $3.49 billion.
Shares of Endo International PLC (NASDAQ:ENDP) opened at 9.31 on Tuesday. The firm’s market capitalization is $2.08 billion. The firm’s 50 day moving average is $11.45 and its 200 day moving average is $11.76. Endo International PLC has a 1-year low of $9.21 and a 1-year high of $24.93.
Endo International PLC (NASDAQ:ENDP) last released its earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. The company had revenue of $875.73 million for the quarter, compared to analysts’ expectations of $832.66 million. During the same quarter in the previous year, the business posted $0.86 EPS. The business’s revenue for the quarter was down 4.9% on a year-over-year basis. Analysts anticipate that Endo International PLC will post $3.53 EPS for the current fiscal year.
Several equities research analysts recently weighed in on ENDP shares. Canaccord Genuity reiterated a hold rating and set a $14.00 price target on shares of Endo International PLC in a report on Tuesday, April 11th. Mizuho restated a buy rating and issued a $18.00 target price (up from $17.00) on shares of Endo International PLC in a research note on Thursday, April 13th. Vetr lowered Endo International PLC from a strong-buy rating to a hold rating and set a $11.34 target price for the company. in a research note on Thursday, April 27th. BMO Capital Markets restated a hold rating and issued a $15.00 target price on shares of Endo International PLC in a research note on Monday, May 1st. Finally, Zacks Investment Research upgraded Endo International PLC from a sell rating to a hold rating in a research note on Tuesday, May 2nd. Three analysts have rated the stock with a sell rating, fifteen have issued a hold rating and six have assigned a buy rating to the company. Endo International PLC currently has a consensus rating of Hold and an average price target of $17.33.
ILLEGAL ACTIVITY WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/08/08/endo-international-plc-nasdaqendp-issues-fy17-earnings-guidance.html.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.